Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

2 treatments under study, led by Reolysin

Related Conditions

Often studied with 6 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 37/100

Termination Rate

0.0%

0 terminated out of 2 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed with results

Key Signals

1 with results100% success

Data Visualizations

Phase Distribution

2Total
Phase 2 (2)

Trial Status

Completed2

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 2 completed trials

Clinical Trials (2)

Showing 2 of 2 trials
NCT00503295Phase 2Completed

Safety and Efficacy Study of REOLYSIN® in the Treatment of Bone and Soft Tissue Sarcomas Metastatic to the Lung

NCT00400569Phase 2Completed

Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma

Showing all 2 trials

Research Network

Common Treatments

  • Reolysin1
  • Sunitinib Malate1

Active Sponsors

  • Pfizer1
  • H. Lee Moffitt Cancer Center and Research Institute1
  • Oncolytics Biotech1

Top Investigators

Related Conditions

  • Fibrosarcoma2
  • Leiomyosarcoma2
  • Ewing Sarcoma Family Tumors1
  • Osteosarcoma1
  • Liposarcoma1

Activity Timeline